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Background: End-stage renal disease (ESRD) patients receiving dialysis are at particular risk for infection. We
assessed the clinical and economic burden of pneumonia in a population of Medicare-enrolled ESRD patients with
respect to incidence and case fatality rates, rates of all-cause and cardiovascular hospitalization, and costs.
Methods: Patients received dialysis between 01 January 2009 and 31 December 2011 and were enrolled in
Medicare Parts A and B. Pneumonia episodes were identified from institutional and supplier claims. Patients were
considered at-risk from first date of Medicare coverage and were censored upon transplant, withdrawal from
dialysis, recovery of renal function, loss of Medicare benefits, or death. Linear mixed-effects models were used to
assess hospitalization rates and costs over the 3 months prior to and 12 months following pneumonia episodes.
Results: The pneumonia incidence rate for the study period was 21.4 events/100 patient-years; the majority of
episodes (90.1%) required inpatient treatment. The 30-day case fatality rate was 10.7%. Compared to month -3 prior
to event, rates of all-cause and cardiovascular hospitalization were higher in the month of the pneumonia episode
(IRR, 4.61 and 4.30). All-cause admission rates remained elevated through month 12; cardiovascular admission rates
remained elevated through month 6. Mean per-patient per-month costs were $10,976 higher in the month of
index episode compared to month -3, largely driven by increased inpatient costs, and remained elevated through
end of 12-month follow-up.
Conclusion: Pneumonia episodes are frequent among ESRD patients and result in hospitalizations and greater
overall costs to Medicare over the following year.
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End-stage renal disease (ESRD) patients receiving dialysis
constitute an older population, frequently have multiple
comorbid conditions, and their clinical management is
complex. ESRD patients are immunocompromised and
have a very high frequency of healthcare contact, typically
attending in-center hemodialysis treatment 3 times per
week in addition to receiving care in a variety of other set-
tings. Consequently, dialysis patients are at elevated risk for
both contracting and transmitting infections; infections are* Correspondence: scott.sibbel@davita.com
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ESRD patients, accounting for 0.45 admissions per patient-
year and representing one-quarter of all admissions among
hemodialysis patients in 2011–2012 [1].
Approximately 20% of infections in ESRD patients are
attributable to pulmonary causes, including pneumonia,
and evidence suggests that episodes of pneumonia are
associated with particularly high morbidity and mortality
in this population [2–4]. However, many of the studies
assessing pneumonia burden in ESRD patients are based
on data from 10 or more years ago, or are focused on
specific patient subgroups (eg, incident dialysis patients);le is distributed under the terms of the Creative Commons Attribution 4.0
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monia in the overall ESRD patient population is limited.
Episodes of pneumonia frequently result in the need for
hospitalization and increased healthcare utilization. Under
current reimbursement, costs of hospitalizations and other
outpatient and ancillary services incurred as a consequence
of pneumonia episodes are borne by the payor—Medicare
for the vast majority of ESRD patients—and likely represent
a significant economic burden in this already costly patient
population. Several studies have reported the estimated
costs of pneumonia for Medicare beneficiaries in general
[5–7] but have not specifically addressed the economic im-
pact in ESRD patients, for whom costs might be expected
to be higher.
In this study, we have assessed both the clinical and
economic burden of pneumonia in a contemporary
population of Medicare beneficiaries with ESRD.
Methods
This was a retrospective, observational cohort study.
Data were taken from the electronic health records of a
large dialysis organization (LDO) and from the United
States Renal Data System (USRDS) database, which in-
cludes Medicare Part A and B claims. Analyses were
conducted retrospectively using deidentified patient data;
thus, this study was deemed exempt from the require-
ment of ethical approval by the institutional review
board (Quorum Review, Seattle, WA, USA). We adhered
to the Declaration of Helsinki; informed consent was
not required.
Analyses were conducted in increasingly restrictive co-
horts based on availability of necessary data elements
(Additional file 1: Figure S1).
Analyses of pneumonia incidence and episode length
Patients included were those who between 01 January
2009 and 31 December 2011: 1) received dialysis at the
LDO; 2) concurrently, were enrolled in Medicare Parts A
and B; and 3) were ≥18 years. Patients were considered at-
risk from the first date on which enrollment criteria were
met until end of study (31 December 2011) or censoring
(for transplant, withdrawal from dialysis, recovery of renal
function, loss of Medicare benefits, or death).
Pneumonia episodes were identified from Medicare
claims considering ICD-9 diagnosis codes 480.x-486.x or
487.0. Pneumonia was ascribed if there was an inpatient
claim with pneumonia diagnosis code in any position or
an outpatient claim with pneumonia diagnosis in any
position and (±14 days) a claim for chest x-ray (Current
Procedural Terminology [CPT] claim code 71010-71035)
[7]. The date of the corresponding pneumonia claim was
considered the episode start date. Thereafter, consecu-
tive pneumonia claims were considered to represent a
single pneumonia episode until a 90-day period hadelapsed during which there were no additional pneumo-
nia claims. Any subsequent pneumonia claim after this
90-day period was considered to represent a separate
pneumonia episode.
Pneumonia episodes were classified based on the treat-
ment setting: episodes that required inpatient treatment
were defined as those in which at least one inpatient
claim was identified; outpatient episodes were those with
no inpatient claim throughout the entire pneumonia
episode.
Analyses of case fatality rates
These analyses considered the subset of the above pa-
tients who also: 1) had at least one qualifying pneumonia
event during the study period and 2) had received
hemodialysis at LDO within the 90-day period preceding
the qualifying pneumonia event. The latter criterion was
to ensure visibility to death date, which was abstracted
from LDO’s electronic health records.
Patients were eligible to contribute multiple qualifying
pneumonia events. For each event, the at-risk period
began on the episode start date and continued until cen-
soring (criteria above).
Analyses of hospitalizations and healthcare expenditures
These analyses considered patients who 1) had index
pneumonia event on or before 31 December 2010 and 2)
had a 90-day pneumonia-free period preceding the epi-
sode to ensure a baseline pneumonia-free control period
against which post-pneumonia events could be com-
pared. For patients with multiple qualifying pneumonia
events, one was selected at random.
Hospitalizations and healthcare expenditures were
compared between a control pneumonia-free period
(primary analysis: month -3 preceding index pneumonia;
sensitivity analysis months -3 to -1 preceding index
pneumonia) and the period following index pneumonia.
Follow-up continued for 12 months or until censoring.
Hospitalizations were identified from Medicare Part A
claims. Cardiovascular hospitalizations were the subset
of hospitalizations for which the primary diagnosis was
cardiovascular-related (Additional file 1: Table S1).
Healthcare cost data were considered from a Medicare
perspective and were derived from claims data and con-
sidered as cumulative monthly paid amounts. Inpatient
and ancillary service costs were derived from Medicare
Part A Institutional Claims Standard Analytic Files
(SAFs). Outpatient costs and dialysis costs were derived
from both Medicare Part A outpatient files and Part B
Physician/Supplier files.
Statistical analysis
Patient characteristics were described as means, stand-
ard deviations (SDs), medians, and interquartile ranges
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tions for categorical variables.
Pneumonia incidence rates were calculated as rates
(number of episodes/time at risk) and were estimated
with Poisson 95% confidence intervals (CIs). Episode
length was calculated as the number of days between the
episode start date and episode end date. For outpatient
episodes where only a single claim was observed, mean
episode length was specified as 1 day. Case fatality rates
were calculated as the number of all-cause deaths that
occurred within 30 days and within 180 days of the date
of pneumonia diagnosis divided by the total number of
pneumonia episodes.
For qualifying pneumonia episodes, all-cause and
acute cardiovascular event hospital admission rates and
healthcare costs were calculated in each month over the
3 months prior to and 12 months following the episode
index date.
Hospitalization rates and costs before and after pneu-
monia episodes were compared using linear mixed-
effects models including an indicator for sequential
month and a random-effects term for the unique patient
identifier. Models of hospitalization rates were specified
with a log link and a Poisson/negative binomial distribu-
tion; cost models were specified with an identity link
and a Gaussian distribution. Costs were empirically
transformed to meet distributional assumptions and re-
sults were back-transformed and expressed on the native
scale. For all models, primary analyses assessed monthly
estimates referent to month -3 values. Sensitivity ana-
lyses comparing monthly mean estimates to the mean
value over the 3-month period prior to diagnosis (month
-3 to month -1) were also performed.
All analyses were performed using SAS® 9.3 (SAS Institute
Inc, Cary, NC).
Results
Pneumonia incidence and episode length
Baseline characteristics of all eligible patients (N =
231,202) are presented in Table 1. The mean age was
61.0 years (SD, 15.3), and 56.4% were male. Patients
were predominantly white (45.8%) or black (34.4%) and
had been on dialysis for 30.1 months on average.
The overall pneumonia incidence rate was 21.4 events
per 100 patient-years (Fig. 1). There were no significant
temporal trends in incidence rates across the years of
study (2009–2011; data not shown). The majority of epi-
sodes (81,883 of 90,862; 90.1%) required inpatient treat-
ment; this corresponded to an incidence rate of 19.3
events per 100 patient-years. A total of 8979 episodes re-
quired outpatient treatment only (incidence rate, 2.1
events per 100 patient-years). Stratification by age re-
vealed that incidence rates of pneumonia were higher
among older patients.Overall, the median episode length was 11 days (Table 2).
Episodes requiring inpatient treatment were longer (median
episode length 12 days), which included a median hospital
stay of 8 days. Pneumonia episodes treated solely in the
outpatient setting were substantially shorter, with a median
length of 1 day, indicating a single pneumonia-related en-
counter (not including the imaging procedure required def-
initionally to ascribe pneumonia). Mean episode duration
among these patients was 8.3 days, indicating the influence
of a small number of protracted episodes.Case fatality rates
The characteristics of 39,988 patients who had pneumo-
nia while concurrently dialyzing at the LDO are pre-
sented in Table 1. Among these patients, the overall 30-
and 180-day case fatality rates were 10.7% and 24.8%, re-
spectively (Fig. 2a and b). Stratifying by age revealed
large differences in case fatality rates across the age
groups, with rates increasing as a function of age. Case
fatality rates were higher for episodes requiring inpatient
treatment compared to episodes treated solely in the
outpatient setting (30-day rates of 11.2% vs 5.9% and
180-day rates of 25.4% vs 18.8%, respectively).Hospitalizations and healthcare expenditures
A total of 19,597 patients contributed 1 qualifying pneumo-
nia episode each for comparisons of hospitalizations and
healthcare expenditures. Figure 3 and Additional file 1:
Table S2 show the rates of all-cause hospital admission and
admission for cardiovascular events before and after pneu-
monia episodes. Crude rates of all-cause hospital admission
increased from 308.5 per 100 patient-years in month -3 to
409.1 events per 100 patient-years in month -1 and peaked
in the month of index pneumonia episode at 1428.5 events
per 100 patient-years (IRR, 4.61; 95% CI, 4.46, 4.76, referent
to month -3). Rates declined thereafter, but remained sig-
nificantly elevated relative to baseline over the 1-year
follow-up period. Cardiovascular event hospitalization rates
followed a similar pattern, with crude rates increasing from
39.6 to 56.6 admissions per 100 patient-years from month
-3 to month -1, reaching 170.5 admissions per 100 patient-
years in the month of the pneumonia episode (IRR, 4.30;
95% CI, 3.93, 4.71, referent to month -3). Cardiovascular
admission rates declined thereafter and were no longer sig-
nificantly elevated compared to baseline by month +3 and
normalized by month +7.
Sensitivity analyses showed that in the month of index
pneumonia event, all-cause hospitalization rates were ap-
proximately 4-fold higher (IRR, 3.97; 95% CI, 3.89, 4.04)
and cardiovascular event hospitalization rates were greater
than 3-fold higher (IRR, 3.55; 95% CI, 3.35, 3.76) than dur-
ing the 3-month period immediately preceding pneumo-
nia (ie, months -3 to -1; Additional file 1: Table S2).









mean ± SD 61.0 ± 15.3 64.6 ± 14.9
median (p25, p75) 62 (51, 72) 66 (55, 76)
Sex, n (%)
Male 130,255 (56.4) 21,602 (54.0)
Female 100,738 (43.6) 18,383 (46.0)
Race/Ethnicity, n (%)
White 105,733 (45.8) 18,426 (46.1)
Black 79,503 (34.4) 13,314 (33.3)
Hispanic 29,028 (12.6) 5408 (13.5)
Asian 6634 (2.9) 1065 (2.7)
Other/unknown 10,095 (4.4) 1772 (4.4)
Dialysis vintage, months
mean ± SD 30.1 ± 39.6 44.1 ± 41.2
median (p25, p75) 18 (1, 44) 34 (14, 62)
Body mass index, kg/m2
mean ± SD 28.1 ± 7.3 26.9 ± 7.0
median (p25, p75) 26.7 (22.9, 31.8) 25.6 (22.1, 30.3)
Body weight, kg
mean ± SD 81.3 ± 22.9 77.0 ± 21.4
median (p25, p75) 77.6 (65.1, 93.5) 73.5 (62.1, 88.0)
Access type, n (%)
Arteriovenous fistula 53,819 (23.3) 18,953 (47.4)
Arteriovenous graft 21,322 (9.2) 8302 (20.8)
Central venous catheter 37,334 (16.2) 10,588 (26.5)
Peritoneal dialysis
catheter
8953 (3.9) 2122 (5.3)
Unknown 109,565 (47.4) 20 (0.1)
Etiology end-stage renal
disease, n (%)
Diabetes 97,779 (42.3) 18,769 (46.9)
Hypertension 66,305 (28.7) 11,341 (28.4)
Other/unknown 66,909 (29.0) 9875 (24.7)
Diabetes, n (%) 144,827 (62.7) 28,507 (71.3)
Coronary artery disease,
n (%)
11,503 (5.0) 4118 (10.3)
Atherosclerosis, n (%) 7059 (3.1) 2389 (6.0)
Atrial fibrillation, n (%) 110 (0.1) 27 (0.1)
Cardiac arrest, n (%) 218 (0.1) 88 (0.2)
Ischemic heart disease,
n (%)
15,340 (6.6) 5266 (13.2)
Cerebrovascular disease,
n (%)
1067 (0.5) 376 (0.9)
Table 1 Baseline Characteristics of Study Cohorts (Continued)
Myocardial infarction,
n (%)
281 (0.1) 101 (0.3)
Pericarditis, n (%) 118 (0.1) 36 (0.1)
Cancer (any cause),
n (%)
3010 (1.3) 1020 (2.6)
Congestive heart failure,
n (%)
15,954 (6.9) 5836 (14.6)
CCI score
mean ± SD 5.2 ± 1.8 5.9 ± 1.9
median (p25, p75) 5 (4, 6) 6 (5, 7)
Hemoglobin, g/dL
mean ± SD 11.6 ± 1.4 11.0 ± 1.4
median (p25, p75) 11.6 (10.8, 12.5) 11.1 (10.1, 11.9)
Serum albumin, g/dL
mean ± SD 3.8 ± 0.5 3.6 ± 0.5
median (p25, p75) 3.8 (3.5, 4.1) 3.7 (3.3, 4.0)
Serum phosphate, mg/dL
mean ± SD 5.2 ± 1.6 5.0 ± 1.7
median (p25, p75) 5.0 (4.1, 5.9) 4.7 (3.9, 5.8)
Serum calcium, mg/dL
mean ± SD 8.8 ± 0.7 8.7 ± 0.8
median (p25, p75) 8.8 (8.4, 9.2) 8.7 (8.2, 9.1)
Parathyroid hormone,
ng/mL
mean ± SD 380 ± 394 361 ± 389
median (p25, p75) 271 (176, 446) 261 (166, 419)
Abbreviations: CCI Charlson comorbidity index, LDO large dialysis organization,
p25 25th percentile, p75 75th percentile, SD standard deviation
a At time of study entry
b At time of first qualifying pneumonia episode
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are presented in Fig. 4a and Additional file 1: Tables S3
and S4. Monthly inpatient costs increased from a mean
of $3522 in month -3 to $20,131 in the month of index
pneumonia episode. Costs remained elevated for several
months thereafter, gradually declining to pre-pneumonia
levels by month 6. With the exception of the month of
the index pneumonia episode, median monthly inpatient
costs were stable, indicating that mean costs were pri-
marily driven by a small number of expensive events in
a minority of patients each month. Outpatient costs
remained relatively consistent over time. Mean monthly
ancillary service costs increased from $635 in month -3
to $1738 in the month of pneumonia diagnosis and
remained elevated relative to pre-episode levels through
month +5. Again, median costs were unchanged through
the entire period, suggesting that increased mean costs
were driven primarily by larger increases for some pa-
tients. Dialysis costs fell slightly during the month of the
index event, probably due to treatments missed while
Fig. 1 Incidence Rates of Pneumonia (2009–2011)
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with dialysis treatments were elevated over baseline by
approximately $100 per month.
Modeled mean incremental costs in each month com-
pared to baseline are shown in Fig. 4b and Additional
file 1: Table S4. Referent to month -3, mean total costs
were $330 and $381 per patient per month higher in
months -2 and -1, and $10,976 higher in the month of
index pneumonia episode. Costs declined subsequently
but remained $600 to $800 higher relative to month -3
through the end of 12-month follow-up. Sensitivity ana-
lyses revealed a mean cost increase of $10,741 per pa-
tient per month in the month of the index episode
versus the month -3 to -1 mean value. Again, cost differ-
ences declined in subsequent months, but remained
$400 to $600 greater than the baseline period through
the end of the study.Discussion
In this study, we have used a merged data set combining
USRDS data with LDO electronic health records to enable
a comprehensive assessment of the burden of pneumonia
in the dialysis population over the period 2009–2011 withTable 2 Pneumonia Episode Length
All episodes Episode
Number of events 90,862 81,883
Episode length, days
mean ± SD 29.0 ± 45.9 31.2 ± 4
median [p25, p75] 11 [5, 33] 12 [6, 3
Hospitalized days
mean ± SD 12.8 ± 1
median [p25, p75] 8 [4, 17respect to incidence rates, case fatality, subsequent
hospitalization rates, and costs to Medicare.
The overall incidence rate of pneumonia for the
study period was 21.4 events per 100 patient-years and
is similar to rates that have been previously published
for dialysis patients. For example, Guo et al. reported
an incidence rate of 27.9 episodes per 100 patient-
years in incident dialysis patients over the period
1996–2001 [2]. The slightly lower rate observed in the
current study likely reflects the fact that our study was
not limited to incident dialysis patients. Two studies
examining community-acquired pneumonia (CAP) in
the general Medicare fee-for-service population re-
ported incidence rates of 4.5 and 4.7 per 100 patient-
years for the time periods 2007–2008 and 2005–2007,
respectively [6, 7]. The dramatically greater pneumo-
nia incidence rate in dialysis patients is probably the
result of multiple, interacting factors. Patients with
ESRD have a greater comorbidity burden than the
general population. Dialysis patients are also at par-
ticularly high risk for disease transmission due to fre-
quent healthcare contact. Finally, these patients have
compromised immune function, which makes them
more susceptible to infections [8]. In comparing thes requiring inpatient stay Episodes treated in outpatient
setting only
8979
7.4 8.3 ± 19.5
6] 1 [1, 8]
5.2
]
Fig. 2 Case Fatality Rates Within 30 Days (panel a) and 180 Days (panel b) of Pneumonia Episode
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to those reported elsewhere in the literature, it also
should be noted that our study was not restricted to
CAP episodes; given that dialysis patients spend up to
12 h per week in healthcare facilities, the distinction
between community-acquired and nosocomial disease
may be artificial in this patient population.Fig. 3 All-Cause and Cardiovascular Event Hospitalization in the Peripneum
hospitalization. Panel b shows relative rates of all-cause hospitalization rela
relative to month -3. Abbreviations: CI, confidence interval; CV, cardiovascuThe proportion of pneumonia episodes requiring in-
patient treatment in our study was approximately 90%,
which was noticeably higher than other studies. Previous
studies have reported that inpatient cases comprised 42% of
pneumonia episodes for dialysis patients [2] and 39 to 47%
for the general Medicare population [6, 7]. The lower rate
of episodes requiring inpatient treatment in the generalonia Period. Panel a shows absolute rate of hospitalization and CV
tive to month -3. Panel c shows relative rates of CV hospitalization
lar; IRR, incidence rate ratio; ref, referent
Fig. 4 Overall and Component Costs in the Peripneumonia Period. Panel a shows mean raw component costs. Panel b shows difference in
overall monthly costs relative to month -3. Abbreviations: CI, confidence interval; USD, US dollars
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comorbidity burden of the ESRD population. It is likely that
the difference between our estimate and those from prior
studies of ESRD patients is, at least in part, due to differ-
ences in operational definitions of pneumonia episodes.
We observed 30- and 180-day case fatality rates for
pneumonia episodes overall of 10.7 and 24.8%, respect-
ively. Rates increased with patient age and were higher
for episodes that required inpatient care than for those
treated solely in the outpatient setting. These rates are
generally consistent with several prior studies of ESRD
patients [2–4].
Among patients with a qualifying pneumonia episode, we
observed rates of all-cause hospitalization that were 4.6-fold
higher in the month of the index pneumonia episode com-
pared to the month -3 baseline. Rates of hospitalization for
acute cardiovascular events were also observed to increase
over 4-fold in the month of pneumonia diagnosis. These
substantial increases are particularly striking, considering
that the cohort of dialysis patients who developed pneumo-
nia already had elevated baseline hospitalization rates—at
309 admissions/100 patient-years in month -3, compared
to 174 admissions per 100 patient-years reported for the
hemodialysis population in 2012 [1]. The fact that patients
who developed pneumonia were generally older, and had
lower body mass index, serum albumin, and hemoglobin
levels than the study cohort overall provides a plausible ex-
planation for these elevated baseline admission rates. All of
these characteristics are typical of the protein-energy wast-
ing/malnutrition-inflammation complex, which is common
among patients with chronic kidney disease and has been
shown to be associated with increased overall and cardio-
vascular morbidity and mortality risk [9].
The observed increase in cardiovascular hospitalization
rate following pneumonia episodes confirms that not all ofthe increase in hospital admissions can be attributed to
pneumonia-related events and, moreover, is consistent
with accumulating evidence of a relationship between
pneumonia and increased risk of subsequent cardiovascu-
lar complications [2, 10, 11]. While the exact mechanism
linking pneumonia with cardiovascular events has yet to
be determined, the persistent inflammatory state induced
by infections such as pneumonia and sepsis is a leading
hypothesis, and infections have specifically been linked to
cardiovascular mortality risk in dialysis patients [12–14].
Prior studies of the economic consequences of pneu-
monia have focused on the general Medicare popula-
tion and have not specifically addressed costs in ESRD
patients [5–7]. The total incremental cost, which con-
sidered all inpatient, outpatient, ancillary, and dialysis
services costs relative to utilization in month -3 prior
to pneumonia diagnosis, accumulated to approximately
$20,000 over the year following a pneumonia episode.
Month -3 was selected as the referent month for pri-
mary analyses to account for increases in healthcare
utilization that may occur in the months immediately
prior to pneumonia diagnosis. However, when costs
were considered relative to the mean of the 3-month
period comprising months -3 to -1— ie, a more conser-
vative approach—the incremental costs still amounted
to approximately $17,000. Incremental costs were
largely driven by high inpatient costs incurred within
the 3 months following the pneumonia diagnosis. How-
ever, there are clearly longer-term economic conse-
quences as well, given that total costs remained
elevated over baseline through the end of the 12-month
follow-up period.
Our study was not without limitations. Administrative
claims data were used for these analyses and may not be
complete in all cases. Pneumonia episodes were defined
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senting a single episode until a period of 90 days had
elapsed, during which there were no claims for pneumo-
nia; any comparison of the incidence rates presented
here with rates derived from other studies should take
into account differences in episode definitions. To assess
hospitalizations and healthcare costs following pneumo-
nia episodes, a 90-day pneumonia-free baseline period
was required for episodes to be included. Although this
limited our analysis to patients with episodes meeting
these criteria, the study design meant that patients
served as their own controls, eliminating the need for
covariate adjustment. Our analyses of the economic con-
sequences of pneumonia were considered in the context
of current reimbursement and pertain only to Medicare
patients in the US. Finally, we were not able to identify
the etiologic organism responsible for pneumonia epi-
sodes, as this information was not present in the admin-
istrative data used for this study.
Conclusions
Overall, the results of our study demonstrate that pneumo-
nia poses a significant clinical and economic burden among
ESRD patients. More than 1 in 5 patients die within
180 days of pneumonia diagnosis, and hospitalization rates
remain elevated over baseline rates for at least 1 year. Based
on the incidence rates and incremental costs observed here,
the overall annual cost to Medicare associated with pneu-
monia among ESRD patients is very substantial. Thus, in-
creased focus on all types of pneumonia prevention
measures—including vaccination—particularly among the
frailest patients, clearly represents an opportunity to im-
prove outcomes among ESRD patients receiving dialysis.
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